Pluristem (PSTI) and NYU Medical Center Partner to Study Use of PLX Cells
PSTI and New York University (NYU) Medical Center formed a partnership to study the use of placenta-derived PLX cells for the treatment of Diabetic Foot Ulcers (DFU).
- An in vitro and a series of animal models will be used to evaluate the role PLX cells have in healing DFU;
- Through a novel academic-industrial collaborative research paradigm, these trials, with proposed support from the NIH will be used as a bridge towards the potential treatment of patients with diabetic foot ulcers.
The Bottom Line: Many diabetic patients have advanced atherosclerosis and have lower extremity vascular insufficiencies. PSTI’s PLX cells can stimulate angiogenesis, which is highly advantageous in treating diabetic chronic wounds. The PLX cells can directly address cellular impairment in diabetic wounds leading to tissue regeneration in the wound beds. The Center for Disease Control (CDC) reports that approximately 12% of patients afflicted with diabetes develop a foot ulcer. This translates into approximately 2.5M patients with foot ulcers in the US alone. No new therapy for diabetic chronic wounds has been introduced into clinical use since 1998 and there is a critical unmet need for innovative therapies able to accelerate DFU healing, prevent amputation and reduce associated morbidity and mortality.
